Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour

Anticancer Drugs. 2020 Jan;31(1):80-84. doi: 10.1097/CAD.0000000000000844.

Abstract

Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as 'pigmented villonodular (teno)synovitis' is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Doxorubicin / administration & dosage
  • Female
  • Giant Cell Tumor of Tendon Sheath / drug therapy*
  • Giant Cell Tumor of Tendon Sheath / radiotherapy
  • Giant Cell Tumor of Tendon Sheath / surgery
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Indazoles
  • Pyrimidines / therapeutic use
  • Radiotherapy, Adjuvant
  • Sarcoma
  • Soft Tissue Neoplasms / drug therapy*
  • Soft Tissue Neoplasms / radiotherapy
  • Soft Tissue Neoplasms / surgery
  • Sulfonamides / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Indazoles
  • Pyrimidines
  • Sulfonamides
  • pazopanib
  • Doxorubicin
  • Imatinib Mesylate
  • olaratumab